An Alzheimer's drug developed by Eli Lilly slowed cognitive and functional decline for people with early stages of the disease, a study that could lead to a new commercially available drug for the ...

I n a May 3 press release, Eli Lilly announced encouraging results from its latest study of its Alzheimer’s drug candidate, donanemab. In the Phase 3 study, which included more than 1,000 people ...

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the ...

The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly’s LLY.N donanemab for patients with early Alzheimer’s, making it the second approved drug for slowing th… ...

Eli Lilly's Alzheimer's drug modestly slows disease "I’m thrilled to have different options to help my patients," Dr. Suzanne Schindler, a neurologist at Washington University in St. Louis, told ...

Eli Lilly and Co (LLY.N) said on Monday a small trial of its experimental Alzheimer's drug found that it slowed by about a third the rate of decline in a combined measure of cognition and function ...

Pharmaceutical company Eli Lilly and Co. said Wednesday that its experimental Alzheimer’s drug, donanemab, yielded positive results in a new trial, and could potentially slow the disease’s ...

Eli Lilly and Co. said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5's Bianca Castro talked with Frisco neurologist Dr ...

Lilly gave an in-depth look at the performance of its drug, called donanemab, on Saturday at the International Conference on Alzheimer's and Parkinson's Diseases.

Eli Lilly and Co on Saturday said its experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32% compared with a placebo in a mid-stage trial of ...

Lilly’s shares climbed 11.7% on Jan 11, following encouraging data readout from the AD study as currently no treatments that slow cognitive decline in Alzheimer’s disease patients have been ...

An Alzheimer's drug developed by Eli Lilly slowed cognitive and functional decline for people with early stages of the disease, a study that could lead to a new commercially available drug for the ...